1)Levy-Clarke G, Jabs DA, Read RW et al:Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121:785-796, 2014
2)Wong U, Cross RK:Primary and secondary nonresponse to infliximab:mechanisms and countermeasures. Expert Opin Drug Metab Toxicol 13:1039-1046, 2017
3)厚生労働科学研究(難治性疾患克服研究事業)ベーチェット病に関する調査研究班の班会議より,2012
4)Katsuyama A, Kusuhara S, Nishisho R et al:Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behçet's disease. Clin Ophthalmol 13:521-527, 2019
5)Hanauer SB, Feagan BG, Lichtenstein GR et al:Maintenance infliximab for Crohn's disease:The ACCENT I randomised trial. Lancet 359:1541-1549, 2002
6)Goto H, Zako H, Namba K et al:Adalimumab in active and inactive, non-infectious uveitis:global results from the VISUAL Ⅰ and VISUAL Ⅱ trials. Ocul Immunol Inflamm 27:40-50, 2019